

Role of Terminalia Chebula Fruits Extract in the Antioxidant Status of Diabetic Rats

Shadia Abdel Hamid Fathy^a, Fatma Farag Abdel Hamid^a, Asrar Mohamed Hawas^b,
Osama Ahmed Abbas^c, Monira Mohamed El Refaey^d

^a Professor of Biochemistry, Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.

^b Lecturer of Comparative Physiology, Drug Radiation Research Department, National Centre for Radiation Research and Technology (NCRRT), Atomic Energy Authority, Cairo, Egypt.

^c Lecturer of Biochemistry, Radioisotope Department, Nuclear Research Center (NRC), Atomic Energy Authority (AEA), Cairo, Egypt.

^d Ph.D. student, Cleopatra Hospital, Cairo, Egypt.

ABSTRACT

Terminalia chebula is a traditional medicine belonging to the genus Terminalia, family Combretaceae. It was recorded to have antidiabetic activity. The present work was subjected to investigate the antioxidant status of diabetic rats due to the aqueous extract of *Terminalia chebula* fruits and/or metformin treatment. Malondialdehyde as indicator to lipid peroxidation process, glutathione level and superoxide dismutase activity were measured in rat liver. Free radical capacity and glucose levels were determined in blood samples. Results revealed different responses of oxidant and antioxidant levels in non-diabetic and diabetic rats via *T. chebula* extract and/or metformin treatment. Decrease glucose levels in all diabetic treated groups compared with diabetic rats. *T. chebula* extract treatment significantly lowered glutathione levels except of its combined treatment with metformin in diabetic rats where very high significant increase occurred. Superoxide dismutase levels exhibited significant increase in all metformin treated groups with no significant increase in diabetic treated group with metformin. Significant decrease in free radical capacity was observed but no significant effects occurred in diabetic group and in *T. chebula* extract administrated rats. In conclusion, the combined treatment with *T. chebula* extract and metformin has been effective more than the either single treatment on diabetic rats.

Keywords: Antidiabetes, traditional medicines, metformin, oxidative stress, free radicals.

1. INTRODUCTION

Free radicals such as reactive oxygen species (ROS) are produced as byproducts in aerobic metabolism, and have been implicated in the pathogenesis of many diseases such as diabetes mellitus^[1-4]. ROS can easily initiate the lipid peroxidation of the membrane lipids, causing damage of the cell membrane of phospholipids, lipoprotein by propagating a chain reaction cycle^[5, 6]. Most living species have efficient defense systems to prevent themselves against oxidative stress induced by ROS^[7]. Thus, antioxidants defense systems have coevolved with aerobic metabolism to counteract oxidative damage from ROS. Antioxidants are compounds that prevent the oxidation of essential biological macromolecules by inhibiting the propagation of the oxidizing chain reaction^[8]. The previous studies have shown that the antioxidant properties of plants could be correlated with oxidative stress defense and different human diseases^[9]. There are adverse effects of synthetic antioxidants, therefore researchers have channelled their interest in isolating natural antioxidants^[10] which are very effective to control the oxidative stress and hence prevent the initiation of disease propagation. *Terminalia chebula* is a traditional medicine belonging to the genus Terminalia, family Combretaceae. Many studies have demonstrated that *Terminalia chebula* exhibits a wide range of biological activities, including cardioprotective^[11, 12], antioxidant^[13], free radical scavenging^[14] and hypolipidemic properties^[15]. Compounds that scavenge for free radicals and have membrane stabilizing potential are reported to be effective in ameliorating the progress of biochemical tissue injury^[16].

The present study provides screening the ability about the free radical scavenging capacity of *Terminalia chebula* on diabetic rats and its antioxidant activity with a reference of anti-diabetic drug, metformin.

Material and methods

Animals:-

Male adult albino rats weighing 150–200 g were obtained from united company for chemicals of medical preparation (UCCMA). Animals were housed in polypropylene cages and maintained under standard laboratory conditions with controlled light-dark cycle, room temperature at about 20-30 °C and humidity from 50% to 75%. Balanced animal food and tap water were available. The food was obtained from UCCMA.

Treatments:

Aloxan was obtained from El-Gomhoria Egypt Company, dissolved in saline and adjusted for a single intra-peritoneal dose 120 mg/kg body weight^[17].

Metformin (MF) is an oral anti-diabetic drug. The tablets was crushed and suspended in water to prepare oral doses of 100 mg/kg body weight^[18].

Terminalia chebula aqueous extract (TAE): *T. chebula* fruit were supplied from the Agriculture Research Center, Giza. It had no previous treatment with any pesticides. The dried fruits of *T. chebula* were powdered to get a coarse powder. The dried powder (250 g) was taken in 500 ml distilled water, mixes well and leaves in 40 °C in incubator for 24 hours before use. The mixture put in refrigerator for use at doses of 500 mg/kg body weight^[19, 20] daily for two weeks.

Instruments

The biochemical assay was achieved using Heλios γ UV/VIS Spectrophotometers (England). ESR signals were recorded by using a Bruker EMX spectrometer (X-band) product of Bruker, Germany.

Experimental design:-

Rats were divided into the following groups (eight rats were assigned for each sacrificing):

-Control: no treated group.

-Diabetic rats: animals received a single dose 120 mg/kg body wt of alloxan via intra-peritoneal injection.

-TAE: animals administered with 500 mg/kg body wt TAE daily for two weeks.

-MF: animals administered with 100 mg/kg body wt MF daily for two weeks.

-MF+TAE: animals administered with 100 mg/kg body wt MF and 500 mg/kg body wt TAE daily for two weeks.

-MF treatment: diabetic animals treated with 100 mg/kg body wt MF daily for two weeks.

-TAE treatment: diabetic animals treated with 500 mg/kg body wt TAE daily for two weeks.

-MF+TAE treatment: diabetic animals treated with 100 mg/kg body wt MF and 500 mg/kg body wt TAE daily for two weeks.

Blood glucose was measured after 72 hours of alloxanization by one touch glucometer to confirm diabetes.

Biochemical analysis:-

Lipid peroxidation levels were ascertained by the formation of malondialdehyde (MDA). Sample preparation was performed as described by Sardar et al.^[21]. 0.5 ml of liver homogenate was treated for determination of MDA as described by Yoshioka et al.^[22]. Glutathione (GSH) concentration in liver was estimated according to Beutler et al.^[23]. Determination of superoxide dismutase (SOD) in liver was according to Marklund and Marklund^[24]. Total free radicals capacity (FRC) assay by electron spin resonance technique (ESR) in blood samples were measured according to the method of Heckly^[25, 26].

Statistical analysis:-

Data were analyzed by unpaired two-tailed Student's t-test^[27]. The results were presented as mean ± S.E. *p* value <0.05 was considered significant.

RESULTS

The results indicated that the antioxidant status of control (non diabetic rats) and diabetic rats had been affected by TAE and/or MF treatment.

With high levels of blood glucose in diabetic rats, significant elevation in MDA level and decreasing in GSH content was observed. Whereas, the change in SOD and FRC were not significant as showed in Table 1.

Table (1): Effect of TAE and/or MF on the antioxidant status and glucose levels in control (non diabetic rats) and diabetic rats (mean ± SE):

Groups	MDA (nmol/g)	GSH (mg/g)	SOD (U/g)	FRC (Radical/ g)	Glucose
Cont	52.12 ± 2.77	461.1 ± 22.2	14.77 ± 0.82	4.101 ± 0.17	119.4 ± 2.154
TAE	57.64 ± 3.51	392.0 ± 19*	13.10 ± 0.68	4.005 ± 0.19	127.5 ± 5.916
MF	48.35 ± 1.10	950.8 ± 27.2***	19.09 ± 0.66**	2.658 ± 0.06***	105.4 ± 1.802***
MF+TAE	56.96 ± 2.381	193.5 ± 2.34***	18.92 ± 0.97*	2.325 ± 0.05***	117.4 ± 2.639
Diabetic (D)	61.18 ± 2.496*	244.8 ± 12.5***	15.93 ± 0.56	3.851 ± 0.18	519.8 ± 28.26***
D+ TAE	65.79 ± 2.03***	224 ± 8.8***	12.08 ± 0.38*#	3.618 ± 0.22*	298.1 ± 22.42***#
D+MF	57.91 ± 1.265	388.2 ± 21.2*#	16.14 ± 0.58	2.903 ± 0.16***#	171.3 ± 7.375***#
D+MF+ TAE	41.17 ± 2.587*#	851.2 ± 68.0***#	17.75 ± 0.49*#	2.627 ± 0.09***#	164.6 ± 2.878***#

* *p* ≤ 0.05, ** *p* ≤ 0.005 & *** *p* ≤ 0.0005 vs control group.

p ≤ 0.05 vs diabetic rat group.




Fig.1: Effect of TAE and/or MF on liver MDA levels in control (non diabetic rats) and diabetic rats: no significant effect of TAE and/or MF on MDA was found in the control. Diabetic treated group with TAE resulted in very highly significant increase in MDA levels while no significant effect occurred with MF treatment. The combined treatment lowered significantly MDA levels. Diabetic rats show significant increase in MDA level.




Fig.2: Effect of TAE and/or MF on liver GSH levels in control (non diabetic rats) and diabetic rats: lowering in GSH levels was observed in non-diabetic rats after administration with TAE or TAE combined with MF, where MF administration led to highly elevation in GSH. Diabetic rats showed very high significant decrease in GSH levels. Compared with diabetic rats, MF treatment improved the GSH concentration. Very high significant increase in GSH levels was observed after the combined treatment with TAE and MF compared with control or diabetic rats.




Fig.3: Effect of TAE and/or MF on liver SOD levels in control (non diabetic rats) and diabetic rats: SOD activity had not been affected in diabetic rats or after administration of TAE, while MF as single administration or combined with TAE significantly increased SOD activity. There was decrease in SOD in diabetic treated group with TAE but the combined treatment with MF caused increase in SOD activity compared with control or diabetic rats.




Fig.4: Effect of TAE and/or MF on FRC in blood in control (non diabetic rats) and diabetic rats: no significant effect occurred in diabetic rats or in TAE administrated group. A very high significant decrease was observed after MF treatment and after its combined treatment with TAE against control and diabetic rats. TAE caused decrease in FRC in diabetic rats.




Fig.5: Effect of TAE and/or MF on blood glucose levels in control (non diabetic rats) and diabetic rats: very high significant increase in glucose levels in diabetic treated groups with TAE and/or MF compared with control. Compared with diabetic rats, very high significant decrease in glucose levels occurred in diabetic treated groups with TAE and/or MF. Single administration with MF for control highly significantly decreased glucose level but no significant effect after TAE administration.

DISCUSSION

Results of the present work revealed that treatment of alloxan induced diabetic rats with aqueous extract of *T. chebula* significantly reduced the hyperglycemia. This result agrees with that of Rao and Nammi^[28] who demonstrated the dose dependent hypoglycemic effect of chloroform extract of *T. chebula* seeds on streptozotocin-induced diabetic rats. Also, Murali et al.^[29] found that oral administration of aqueous extract of *T. chebula* reduced the elevated blood glucose by 43.2% whereas, Lee et al.^[30] demonstrated the antihyperglycemic effect of aqueous extract of *T. chebula*. There is growing evidence that oxidation stress is increased in diabetes due to the overproduction of ROS, and decreased efficiency of antioxidant defenses^[31]. Glycation is a reaction which occurs during diabetes^[32]. This reaction begins with adduction of a reducing sugar to an amino group in protein, and finally proceeds to form advanced glycation end products. Advanced glycation end products can mediate their effects via specific receptors, thereby activating diverse signal transduction cascades which can lead to the generation of ROS^[32]. Pazdro and Burgess^[33] reported that oxidation of lipids, proteins, macromolecules and DNA occurs during the development of diabetes. El-Missiry et al.^[34] reported that alloxan administration significantly increased lipid peroxidation products.

In the present study, diabetic rats had been suffered from oxidative stress by increasing of liver MDA level. Also the hepatic GSH concentration was decreased significantly in the diabetic rats with respect to the control which is in agreement with the previous studies^[35-37, 20]. Maritim et al.^[35] reported that the high levels of MDA in the diabetic rats might contribute to the impaired glutathione defenses.

Aqueous extract of *T. chebula* have been characterized by high phenolic content^[38]. In non-diabetic rats, TAE as a natural product had been able to maintain MDA, SOD, FRC and glucose levels with slight significant decrease in GSH levels. In the present study, despite of the high phenolic content of TAE, the liver concentration of GSH was highly decreased after its administration to diabetic rats. TAE as single exposure (500 mg/kg body wt for two weeks) can not restore the oxidative stress effect of alloxan in diabetic rats whereas it reduced blood glucose level but not restores its normal level. ROS radicals are toxic to cells, particularly the cell membrane in which these ROS are involved in lipid peroxidation^[39]. In the mitochondria, the excessive levels of glucose lead to an overdrive of the electron transport chain, resulting in the formation of excess superoxide anions^[40]. Treating mice with total extracts of medicinal plants as *T. chebula* increased the activity of antioxidant enzymes as SOD and GSH, where these enzymes are modulated in various diseases by free radical attack, thus maintaining the balance between the rates of radical generation and scavenging^[8]. The results of the present study showed that treatment of diabetic rats with TAE and/or metformin reduced significantly glucose levels compared with its level in diabetic rats, whereas the combined effect of them inhibited lipid peroxidation process and FRC while elevation in GSH level and SOD activity was observed.

Cells are normally protected against oxidative damage by multiple enzymatic mechanisms and by antioxidant molecules. The SOD is the first and most important line of antioxidant enzyme defense systems against ROS and particularly superoxide anion radicals^[41]. SOD catalyzes the breakdown of $O_2\cdot^-$ to O_2 and H_2O_2 , and thus prevents the formation of OH, and thereby, has been implicated as an essential defense against the potential oxygen toxicity^[8].

In the present work, SOD activity showed no significant change in diabetic rats, while it increased significantly in normal rats treated with metformin alone, or metformin with aqueous extract of *T. chebula* compared to control group. Meanwhile, SOD activity decreased significantly in diabetic rats treated with aqueous extract of *T. chebula* alone compared to the untreated diabetic group. This decrease in SOD activity may be attributed to the induction of diabetes in rats with alloxan which uniformly results in an increase of ROS that extrapolated antioxidant capacity of SOD. In response to oxidative stress, SOD behaves in two different ways. Initially, the body reacts during a moderate oxidative stress by over expression of SOD (e.g. exercise). If the stress persists and produces a massive toxic of oxygen active species, SOD will be destroyed and its concentration will drop. Paradoxically, an excessive concentration of SOD may be dangerous because, in this case, it is the basis of an overproduction of hydrogen peroxide (paradoxical effect of antioxidants)^[42].

Maritim et al.^[35] recorded that nonenzymatic glycation may also alter the structure and function of antioxidant enzymes such that they are unable to detoxify free radicals, exacerbating oxidative stress in diabetes. In this respect, lysine residue in the active site of the SOD is non-enzymatically glycosylated (glycation) in the presence of hyperglycemia, decreasing SOD activity^[43].

Cheng et al.^[14] indicated that no antioxidant activity of casuarinin, chebulanin, chebulinic acid or 1,6-di-O-galloyl- β -D-glucose, isolated and purified from *T. chebula*, had been reported. When evaluated for antioxidant activity, an interesting result was observed among the tested pure compounds. It was found that tested pure compounds, in some terms, were specific in their antioxidant activity. For example, although casuarinin was active in scavenging free radicals, its anti-superoxide formation and anti-lipid peroxidation activities were moderate or weak. For chebulanin, the inhibitory effects on the peroxidation of lipids and the formation of superoxide radicals were more significant than that on the scavenging of free radicals.

In this work, a highly significant decrease in free radical capacity was observed after Metformin treatment alone or in combination with an aqueous extract of *T. chebula* for normal and diabetic rats compared to control group.

Hyperglycemia can promote an important oxidative imbalance, favoring the production of free radicals and reduction of antioxidant defenses. At high concentrations, ROS/RNS can lead to damage of major components of the cellular structure, including nucleic acids, proteins, amino acids and lipids. Such oxidative modifications in diabetes condition would affect several cell functions, metabolism and gene expression, which can cause other pathological conditions^[44].

In conclusion, the combined treatment with aqueous extract of *T. chebula* and metformin has been effectiveness more than the either single treatment on diabetic rats whereas the treatment by aqueous extract of *T. chebula* alone have not able to recomposed the adverse effect of diabetes on the antioxidant status. The synergistic action of the combination of *T. chebula* and metformin need further study.

Acknowledgment

This study was performed in the National Centre for Radiation Research and Technology-Atomic Energy Authority, Cairo, Egypt.

REFERENCES

1. Bagchi, D., M. Bagdhi, S.J. Hassoun and S.J. Stochs, 1995. In vitro and in vivo generation of reactive oxygen species, DNA damage and lactate dehydrogenase leakage by selected pesticides. Toxicology, 104: 129-140.
2. Halliwell, B. and J.M.C. Gutteridge, 1984. Lipid peroxidation, oxygen radicals, cell damage, and antioxidant therapy. Lancet, 1: 1396-1397.
3. Lee, S., I. Suh and S. Kim, 2000. Protective effects of the green tea polyphenol (-)-epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils. Neuroscience letters, 287: 191-194.

4. Wallace, D.C., 1999. Mitochondrial diseases in man and mouse. *Science*, 283: 1482-1488.
5. Braca, A., C. Sortino, M. Politi, I. Morelli and J. Mendez, 2002. Antioxidant activity of flavonoids from *Licania licaniaeflora*. *Journal of Ethnopharmacology*, 79: 379-381.
6. Maxwell, S.R., 1995. Prospects for the use of antioxidant therapies. *Drugs*, 49: 345-361.
7. Niki, E., H. Shimaski and M. Mino, 1994. Antioxidantism-free radical and biological defense. Gakkai Syuppan Center, Tokyo, pp: 3-16.
8. Hazra, B., R. Sarkar, S. Biswas and N. Mandal, 2010. Comparative study of the antioxidant and reactive oxygen species scavenging properties in the *Terminalia chebula*, extracts of the fruits of *Terminalia bellerica* and *Emblica officinalis*. *BMC Complementary and Alternative Medicine*, 10:20.
9. Finkel, T. and N.J. Holbrook, 2000. Oxidants, oxidative stress and the biology of ageing. *Nature*, 408: 239-247.
10. Kuo, P.C., A.G. Damu, C.Y. Cherng, J.F. Jeng, C.M. Teng, E.J. Lee and T.S. Wu, 2005. Isolation of a natural antioxidant, dehydrozingerone from *Zingiber officinale* and synthesis of its analogues for recognition of effective antioxidant and antityrosinase agents. *Archives of pharmacal research*, 28: 518-528.
11. Suchalatha, S. and C.S. Shyamala Devi, 2004. Protective effect of *Terminalia chebula* against experimental myocardial injury induced by isoproterenol. *Indian journal of experimental biology*, 42: 174-178.
12. Suchalatha, S. and C.S. Shyamala Devi, 2005. Protective effect of *Terminalia chebula* against lysosomal enzyme alterations in isoproterenol-induced cardiac damage in rats. *Experimental and clinical cardiology*, 10(2): 91-95.
13. Kato, Y., A. Nagao, J. Terao and T. Osawa, 2003. Inhibition of myeloperoxidase-catalyzed tyrosylation by phenolic antioxidants in vitro. *Bioscience, biotechnology, and biochemistry*, 67: 1136-1139.
14. Cheng, H.-Y., T.-C. Lin, K.-H. Yu, C.-M. Yang and C.-C. Lin, 2003. Antioxidant and free radical scavenging activities of *Terminalia chebula*. *Biological & pharmaceutical bulletin*, 26: 1331-1335.
15. Shaila, H.P., S.L. Udupa and A.L. Udupa, 1998. Hypolipidemic activity of three indigenous drugs in experimentally induced atherosclerosis. *International journal of cardiology*, 67: 119-24.
16. Munasinghe, T.C., C.K. Seneviratne, M.I. Thabrew and A.M. Abeyssekera, 2001. Antiradical and antilipoperoxidative effects of some plant extracts used by Sri Lankan traditional medical practitioners for cardioprotection. *Phytotherapy research*, 15: 519-523.
17. El-Demerdash F., M. Yousef and N. El-Naga, 2005. Biochemical study on the hypoglycemic effects of onion and garlic in alloxan-induced diabetic Rats. *Food and chemical toxicology*, 43(1): 57-63.
18. Cheng, J.T., C.C. Huang, I.M. Liu, T.F. Tzeng and C.J. Chang, 2006. Novel Mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. *Diabetes*, 55: 819-825.
19. Lee, H.S., N.H. Won, K.H. Kim, H. Lee, W. Jun and K.W. Lee, 2005. Antioxidant effects of aqueous extract of *Terminalia chebula* in vivo and in vitro. *Biological & pharmaceutical bulletin*, 28(9): 1639-1644.
20. Kim, J., C.O. Hong, Y. Koo, S.J. Kim and K.W. Lee, 2011. Oral administration of ethyl acetate-soluble portion of *terminalia chebula* conferring protection from streptozotocin-induced diabetic mellitus and its complications. *Biological & pharmaceutical bulletin*, 34(11): 1702-1709.
21. Sardar, S., A. Chakraborty and M. Chatterjee, 1996. Comparative effectiveness of vitamin D3 and dietary vitamin E on peroxidation of lipid and enzymes of the hepatic antioxidant system in Sprague-Dawley rats. *International journal for vitamin and nutrition research*, 66: 39-45.
22. Yoshioka, T., K. Kawada, T. Shimada and M. Mori, 1979. Lipid peroxidation in maternal and cord blood and protective mechanism against activated oxygen toxicity in the blood. *American journal of obstetrics and gynecology*, 135: 372-376.
23. Beutler, E., O. Duron and B.M. Kelly, 1963. Improved method for the determination of blood glutathione. *The Journal of laboratory and clinical medicine*, 61: 882-888.
24. Marklund, S. and G. Marklund, 1974. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. *European journal of biochemistry*, 47: 469-474.
25. Heckly, R.J., 1972. Free radicals in dry tissues. In: *Biological applications of electron spin resonance*. (Eds H. M. Swartz, J. R. Bolton and D.C. Borg) Chapter 5. Wiley-Interscience, a division of John Wiley & Sons, Inc. New York, London, Sydney, Toronto.
26. Heckly, R.J., 1976. Free radicals in dry biological systems. In: *Free radicals in biology*. (Ed W.A. Pryor) Volume II. Chapter 4. Academic press. New York, San Francisco, London. A subsidiary of Harcourt Brace. Jovanovich.

27. Kirkwood, B.R., 1988. Comparison of two means. In: Essentials of medical statistics. (Ed B.R. Kirkwood) Blackwell Scientific Publications, pp: 41-45.
28. Rao N. and S. Nammi, 2006. Antidiabetic and renoprotective effects of the chloroform extract of *Terminalia chebula* Retz. Seeds in streptozotocin-induced diabetic rats. BMC Complementary and Alternative Medicine, 6:127-32.
29. Murali Y., P. Anand, V. Tandon, R. Singh, R. Chandra and P. Murthy, 2007. Long-term effects of Terminalia chebula Retz. On hyperglycemia and associated hyperlipidemia, tissue glycogen content and in vitro release of insulin in streptozotocin induced diabetic rats. Experimental and clinical endocrinology & diabetes, 115: 641-646.
30. Lee H.-S., Y.-C. Koo, H.-J. Suh, K.-Y. Kim and K.-W. Lee, 2010. Preventive effects of chebulic acid isolated from *Terminalia chebula* on advanced glycation endproduct-induced endothelial cell dysfunction. Journal of Ethnopharmacology, 131: 567-574.
31. Ramakrishna, V. and R. Jaikhani, 2008. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta diabetologica, 45: 41-46.
32. Tan, A.L.Y., J.M. Forbes and M.E. Cooper, 2007. AGE, RAGE, and ROS in diabetic nephropathy. Seminars in nephrology, 27: 130-143.
33. Pazdro, R. and J.R. Burgess, 2010. The role of vitamin E and oxidative stress in diabete complications. Mechanisms of ageing and development, 131: 276-286.
34. El-Missiry M., A. Othman and M. Amer 2004. L-arginine ameliorates oxidative stress in alloxan-induced experimental diabetes mellitus. Journal of applied toxicology, 24: 93-97.
35. Maritim, A.C., R.A. Sanders and J.B. Watkins, 2003. Diabetes, oxidative stress and antioxidants: a review. Journal of biochemical and molecular toxicology, 17: 24-38.
36. Ewis, S.A. and M.S. Abdel-Rahman, 1995. Effect of metformin on glutathione and magnesium in normal and streptozotocin-induced diabetic rats. Journal of applied toxicology, 15: 387-390.
37. Loven, D., H. Schedl, H. Wilson, T.T. Daabees, L.D. Stegink, M. Diekus and L. Oberley, 1986. Effect of insulin and oral glutathione on glutathione levels and superoxide dismutase activities in organs of rats with streptozocin-induced diabetes. Diabetes, 35: 503-507.
38. Chang, C.L. and C.S. Lin, 2012. Phytochemical composition, antioxidant activity, and neuroprotective effect of Terminalia chebula Retzius extracts. Evidence-Based Complementary and Alternative Medicine, 2012; 2012: 125247.
39. Haugaard, N., 1968. Cellular mechanisms of oxygen toxicity. Physiological reviews, 48: 311-373.
40. Wiernsperger, N.F., 2003. Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Diabetes & metabolism, 29: 579-585.
41. Celino, F.T., S. Yamaguchi, C. Miura, T. Ohta, Y. Tozawa, T. Iwai and T. Miura, 2011. Tolerance of spermatogonia to oxidative stress is due to high levels of Zn and Cu/Zn superoxide dismutase. PLoS ONE, 6(2): e16938.
42. Toma, E., C. Demougeotc, O. Mtopia, T. Dimoa, P. Djomenia, D. Bilandaa, C. Girardb and A. Berthelotc, 2011. The aqueous extract of Terminalia superba (Combretaceae) prevents glucose-induced hypertension in rats. Journal of Ethnopharmacology, 13: 828-833.
43. Arai, K., S. Iizuka, Y. Tada, K. Oikawa and N. Taniguchi, 1987. Increase in the glucosylated form of erythrocyte Cu-Zn-superoxide dismutase in diabetes and close association of the nonenzymatic glucosylation with the enzyme activity. Biochimica et biophysica acta, 924: 292-296.
44. Young, I. and J. Woodside, 2001. Antioxidants in health and disease. Journal of clinical pathology, 54: 176-186.